GOG GYN-LIVE - INDUSTRY SUPPORTED SYMPOSIA

The GOG Foundation, Inc
  • 0.0 (0)
  • Medicine

The GOG Foundation, Inc. and GOG Partners are thrilled to share enduring education from Industry Supported Symposia that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year.

  1. 5d ago

    Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer

    The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to access the Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer Enduring Educational Symposium that was presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Sunday, June 14, 2026. This educational activity is supported by an independent medical education grant from GSK. Course Description The era of antibody–drug conjugates (ADCs) in gynecologic oncology have shifted from promise to intense competition. In ovarian and endometrial cancers, platforms targeting FRα, HER2/HER3, TROP2, B7-H4, CDH6, and NaPi2b are advancing rapidly. Mirvetuximab soravtansine has improved outcomes for FRα-positive ovarian cancer, while trastuzumab deruxtecan has extended HER2-directed therapy to certain endometrial tumors. Next-generation ADCs are improving antigen selection, internalization, payload potency, and linker stability to address antigen heterogeneity, resistance, and class-specific toxicities highlighted in recent studies. This symposium will provide a clear, evidence-based overview of the ADC landscape. Faculty will differentiate competing designs, evaluate key and emerging trial data, and offer practical guidance on sequencing, toxicity management, and biomarker-driven patient selection. The program will also highlight active trials and company strategies shaping future standards of care, ensuring participants are prepared to incorporate ADC advances into practice with confidence and clarity.

    Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer

  2. 5d ago

    The GOG Highlight Reel – July 2026

    The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course examines recent clinical trial data in gynecologic malignancies, offering insights on data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians in comprehending the evolving treatment landscape, including understanding trials in progress. Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions will focus on emerging approved therapies and investigational agents, with an intent to provide insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the skills to navigate the latest oncology research and clinical care confidently. The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: Acrivon, AbbVie, AstraZeneca, Corcept Therapeutics, Eisai, Eli Lilly, Gilead, GSK, Karyopharm Therapeutics, Merck, Pfizer, Verastem

    The GOG Highlight Reel – July 2026

  3. 5d ago

    Evolving Evidence and Treatment Strategies in Low Grade Serous Ovarian Cancer (LGSOC)

    This program provides an in‑depth review of the evolving treatment landscape in ovarian cancer with a focus on emerging science and practical application in patient care. Participants will explore the current competitive landscape, new indications, and recent data surrounding folate receptor alpha–targeted therapies. The session will also look ahead to future developments, including the role of antibody–drug conjugates (ADCs) in low‑grade serous ovarian cancer, MEK inhibitors, and the significance of KRAS mutations. Additionally, the course will address the management of adverse events, dose modifications, and strategies to support patients experiencing treatment‑related reactions. A discussion of biomarkers and considerations for first‑line management of recurrent disease will help clinicians make informed, evidence‑based decisions.

    Evolving Evidence and Treatment Strategies in Low Grade Serous Ovarian Cancer (LGSOC)

  4. 5d ago

    ctDNA-based MRD testing and monitoring in gynecologic cancers

    Molecular residual disease (MRD) tracking via tumor-informed circulating tumor DNA (ctDNA) is redefining the surveillance and management paradigm in gynecologic oncology. This session delivers a data-driven evaluation of the evolving role of ctDNA in identifying subclinical recurrence and quantifying real-time treatment response across ovarian, uterine, and cervical cancers—frequently months ahead of traditional biomarkers and diagnostic imaging. Participants will examine the mechanistic basis of whole-genome and exome-based personalized assay designs, alongside the latest clinical datasets validating their prognostic utility. Through interactive, case-based reviews, faculty will demonstrate how longitudinal ctDNA tracking helps clarify complex clinical scenarios, such as predicting first-line maintenance benefit, identifying platinum sensitivity, and ruling out pseudoprogression during immunotherapy. The presentation will also address critical barriers to integration, including analytical limits of detection, Clonal Hematopoiesis of Indeterminate Potential (CHIP) filtering, and guideline implementation. To ensure a balanced perspective, this course contrasts ctDNA dynamics with traditional modalities, including CA-125 kinetics, investigative imaging cadence, and histopathological risk factors. Attendees will leave equipped to critically interpret molecular testing results and seamlessly integrate personalized genomic data into a multidisciplinary care framework.

    ctDNA-based MRD testing and monitoring in gynecologic cancers

  5. 5d ago

    Precision Decision Making in Platinum Resistant Ovarian Cancer: Folate Receptor Alpha Expression and Other Biomarkers Into Contemporary Care

    Despite advances in ovarian cancer treatment, outcomes for patients with platinum‑resistant disease remains poor, with therapeutic decisions becoming increasingly complex as novel biomarkers and targeted therapies emerge. This 45‑minute case‑based educational program will provide clinicians with practical guidance on integrating folate receptor alpha (FRα) testing into real‑world decision‑making, alongside emerging considerations such as weekly paclitaxel and/or bevacizumab eligibility, PD-L1, HER2 status, and other biologic drivers. Through interactive discussion of patient cases led by two expert faculty, learners will explore how biomarker evaluation, clinical characteristics, and prior therapies influence treatment selection and sequencing, with an emphasis on optimizing outcomes in platinum‑resistant ovarian cancer.

    Precision Decision Making in Platinum Resistant Ovarian Cancer: Folate Receptor Alpha Expression and Other Biomarkers Into Contemporary Care

  6. May 29

    Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer: Charting the Course: Treatment Approaches for dMMR Endometrial Cancer

    This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives treatment selection, the importance of toxicity management, and strategies for sequencing therapies across patient subtypes. The session will conclude with forward-looking perspectives on addressing data gaps and improving outcomes.

    Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer: Charting the Course: Treatment Approaches for dMMR Endometrial Cancer

  7. Feb 9

    Evidence Based Biomarker-Driven Advances in Ovarian & Endometrial Cancer: Equitable, Individualized and Accessible Care

    This course offers a clinically relevant exploration of evolving treatment strategies in ovarian and endometrial cancers for a global audience.  The primary focus of this course will help learners understand how to make biomarker-driven decisions for on-label therapeutic pathways. Learners will deepen their understanding of the role of BRCA, HRD, MMR/MSI, and emerging biomarkers such as p53 for equitable and individualized care treatment plans that aim to improve patient outcomes.   Through cased-based learning, the program emphasizes the real-world application of molecular testing, including how to interpret biomarker results and integrate them into treatment.  Key trials such as SOLO-1, PAOLA-1, PRIMA, DUO-E and ARIEL3 will be discussed to illustrate evidence-based approaches to selecting the right therapy for the right patient, particularly in the context of PARP inhibitor use and HRD testing as well as target based ADCs.  The course acknowledges geographic disparities, particularly in areas with limited on-the-ground support and aims to provide practical guidance for clinicians who are working to implement testing and treatment strategies under local constraints.  Additionally, the program will explore emerging therapeutic targets and biomarkers, including the potential of antibody-drug conjugates (ADCs), Her2 and Folate Receptor Alpha, and discuss how evolving science is reshaping treatment landscapes. Consideration will be given to health equity, access to testing, and the implementation challenges faced by clinicians and patients across diverse care environments.   All content will be aligned with current regulatory guidelines and appropriate for independent medical education (IME), with a clear distinction between on-label use and emerging data requiring further validation.

    Evidence Based Biomarker-Driven Advances in Ovarian & Endometrial Cancer: Equitable, Individualized and Accessible Care

  8. Feb 9

    Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer First Installment

    This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives treatment selection, the importance of toxicity management, and strategies for sequencing therapies across patient subtypes. The session will conclude with forward-looking perspectives on addressing data gaps and improving outcomes.

    Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer First Installment
See All (13)

About

The GOG Foundation, Inc. and GOG Partners are thrilled to share enduring education from Industry Supported Symposia that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year.

Information

  • Creator
    The GOG Foundation, Inc
  • Years Active
    2026
  • Episodes
    13
  • Rating
    Clean
  • Copyright
    © 2026 The GOG Foundation, Inc